The Ming Hsieh Institute for Research on Engineering-Medicine for Cancer (MHI) aims to make USC an international leader in translational research that bridges basic science, engineering, computing, and medicine. The MHI was established in 2010 through a generous gift from Ming Hsieh, a graduate of the USC Viterbi School of Engineering, founder of Cogent Systems and Fulgent Genetics, USC Trustee, and a member of the National Academy of Engineering and the National Academy of Inventors. The central goal of the institute is integrated interdisciplinary translational research that speeds discovery and creates pathways to rapidly improving lives of patients. The MHI is strongly committed to supporting new and creative approaches and breakthrough interdisciplinary ideas that turn advances in engineering, computing, and science into treatments and cures.
To encourage innovative and impactful research, the MHI recognizes the importance of supporting a broad research portfolio of targeted diseases within this solicitation, encompassing approaches that bridge science, engineering, computing, and medicine. To fulfill this aim, we seek proposals with novel therapeutic or diagnostic approaches to detect or treat disease. We seek proposals that will initiate multi-disciplinary research teams that partner engineering, computing, AI/machine learning, computational biology, physics, and/or chemistry with clinicians and biomedical researchers.
|Deadline: 5pm, Monday, January 24, 2022|
View the RFP for full proposal requirements.
Previous awardees can be found at Ming Hsieh Institute.